The 340B Drug Pricing Program, designed to provide support for outpatient drug purchases, severely lacks federal oversight, said BRG Healthcare, the business advisory group, in a report sponsored by the Alliance for Integrity and Reform of 340B (AIR340B). BRG increased its growth estimates for 340B and said the program would exceed billion in total sales by 2021 (Figure 1
). That amount is higher than the total Medicare Part B drug reimbursement in 2014, and the comparison is significant, BRG said, because Medicare Part B currently has significantly more administrative assistance from the Health Resources & Service Administration (HRSA) than 340B receives.
... to read the full story